Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04042103 · ClinicalTrials.gov registry record · Phase 2
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by Organon and.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
- 6
- Study locations
NCT04042103 is a Phase 2 study of Plaque Psoriasis that has completed, run by Organon and. The registered enrollment target is 21 participants, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (95% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT04042103, a Phase 2 study of Plaque Psoriasis, has completed, sponsored by Organon and.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.
Conditions Studied
Interventions
- DRUG Tapinarof cream, 1%
Study Locations (6)
Texas
- Dermavant Investigational Site - Austin
- Dermavant Investigational Site - San Antonio
California
- Dermavant Investigational Site - Encino
Florida
- Dermavant Investigational Site - Sanford
Pennsylvania
- Dermavant Investigational Site - Philadelphia
Washington
- Dermavant Investigational Site - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-07-23 |
| Est. Completion | 2020-01-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04042103
The ClinicalTrials.gov registry entry for NCT04042103 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (95% lower). The listed sponsor is Organon and, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which Tapinarof cream, 1% is the first listed.
NCT04042103 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Texas, California, Florida.
Frequently Asked Questions
What is clinical trial NCT04042103 about?
NCT04042103 is a clinical study titled "Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis". This is an open-label, multicenter study to evaluate the systemic exposure and safety of topical tapinarof cream, 1% under conditions of maximal use in adults with plaque psoriasis.
What is the current status of trial NCT04042103?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2019-07-23. Estimated completion is 2020-01-09.
What conditions does trial NCT04042103 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT04042103?
The interventions under investigation include: Tapinarof cream, 1% (DRUG).
Who is sponsoring clinical trial NCT04042103?
This trial is sponsored by Organon and, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04042103 being conducted?
This trial has 6 study locations across California, Florida, Pennsylvania, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RECRUITING · Phase 2
-
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.